Herborium®’ Group Half Year Update
Herborium Group (OTC Pink: HBRM) announced key accomplishments for the first half of 2022, including the elimination of $200,000 in corporate debt without dilutive financing. The company maintained a strong sales performance, improved margins from 61% to 64%, and developed new business alliances expected to yield returns in 6-12 months. Herborium is transitioning into an AI-based platform for skincare, aiming to capitalize on the growing demand for natural products. This strategic shift is anticipated to enhance market reach and create multiple revenue streams.
- Eliminated $200,000 in corporate debt without dilutive financing.
- Maintained strong sales and improved margins from 61% to 64%.
- Developed new business alliances expected to be monetized in 6-12 months.
- Transitioning to an AI-based skincare platform to leverage growth opportunities in natural products.
- Potential for multiple revenue streams and increased brand recognition from new business model.
- None.
Debt Elimination, Maintaining Sales and New Initiatives In Focus
Houston, July 21, 2022 (GLOBE NEWSWIRE) -- Houston, Texas, 07/21/2022. Herborium Group, Inc. (OTC Pink: HBRM), a Botanical Therapeutics Company and provider of unique, all botanical medicinal, beauty and wellness products with a clinically validated records of efficacy and safety, announced today the following accomplishments for the first half of 2022. The Company also shares with Investors the plan for the remaining months of the year.
- According to prior announced plans, the Company eliminated
$200,000 in corporate debts without dilutive financing or issuing additional corporate shares. The Company will continue its efforts to reduce debt without dilution, possibly retire shares and to increase shareholders value. - The Company stayed current and maintained the Highest Tier of Reporting on OTC. Almost 2000 companies were eliminated from OTC for lack of regulatory compliance and reporting.
- Despite inflationary pressure and other disadvantageous economic factors the Company maintains strong sales during the entire six month period. Herborium improved its margins from
61% of64% and developed some new business alliances. These alliances are expected to be monetized during the next 6-12 months. - During the past six months, the company accelerated its transformation from an Acne Treatment Company to become an interactive, AI based platform for integrated product, content and expertise in the area or skincare: The introduction of the first stage of SKIN-NATURA® is expected in the 4th Quarter of 2022. With a strong global trend towards using natural products, with a
21% growth in on online beauty business since 2018 and over75% of women and over55% of men purchasing their selfcare products online, Herborium’s expansion of its platform opens new growth opportunities for the Company. - Due to Herborium’s unique expertise, the new platform will provide all needed deliverables for consumers and professionals seeking natural alternatives to serious self-care concerns (initially skincare problems) unanswered by traditional providers.
- This innovative technology platform will allow the Company to establish a Consortium of preselected natural products and know-how partners that together provide one of a kind, comprehensive, easy to use and friendly to access one stop shopping for personalized selfcare products. In addition, regimens, treatment options, counseling, advisement, medical and nutritional assistance and a curated consumer forum in the natural wellness and beauty space will be provided.
- This new business model will allow Herborium to realize multiple revenue streams, significantly expand its market reach, increase consumer satisfaction and loyalty as well as create additional shareholders value through revenue growth and increased brand recognition. This initiative will also provide potential for further partnerships and acquisitions.
About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics company that develops, license and markets proprietary, botanical based medicinal and wellness products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products to establish and maintain a differential advantage. Herborium has secured a pipeline of botanical ingredients based products in the areas of dermatological needs, wellness and energy, women’s health and selected sexual disorders and has built the versatile, technologically advanced, interactive content platform to support consumer needs. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce. For more information, please visit www.herborium.com, www.acnease.com, www.acnease.fr and www.acneasesp.com
Safe Harbor Statement: This release contains forward-looking statements with respect to the results of operations and business of Herborium Group, Inc., which involves risks and uncertainties. The Company's actual future results could materially differ from those discussed. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward looking statements be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995.
FAQ
What are Herborium Group's recent accomplishments in 2022?
How is Herborium Group transforming its business model?
What financial metrics did Herborium report for the first half of 2022?
What future opportunities does Herborium Group see?
What is the stock symbol for Herborium Group?
